Intravenous vasoactive intestinal polypeptide lowers pulmonary-to-systemic vascular resistance ratio in a neonatal piglet model of pulmonary arterial hypertension

Journal of Pediatric Surgery

Volumn 42, Issue 5, 2007, Pages 758-764

  Haydar, Sam ^a,b   Sarti, J Fernando ^a,b   Grisoni, Enrique R ^a,b  

^a Banner Desert Medical Center   (United States)

^b ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Meconium aspiration syndrome; Pulmonary arterial hypertension; Vasoactive intestinal polypeptide

Indexed keywords

VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HEMODYNAMICS; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT OUTCOME; VASCULAR RESISTANCE;

ANALYSIS OF VARIANCE; ANIMALS; CARDIAC OUTPUT; DISEASE MODELS, ANIMAL; HEART RATE; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; MECONIUM; RANDOM ALLOCATION; SWINE; VASCULAR RESISTANCE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 34248205245     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2006.12.026     Document Type: Article

References (38)

1. Said S.I., and Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 169 (1970) 1217-1218
2. Said S.I., and Mutt V. Isolation from porcine intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon. Eur J Biochem 28 (1972) 199-204
3. Mutt V., and Said S.I. Structure of the porcine vasoactive intestinal octacosapeptide. The amino-acid sequence. Use of kallikrein in its determination. Eur J Biochem 42 (1974) 581-589
4. Larsson L.I., Fahrenkrug J., Schaffalitzky De Muckadell O., et al. Localization of vasoactive intestinal polypeptide (VIP) to central and peripheral neurons. Proc Nat Acad Sci U S A 73 (1976) 3197-3200
5. Said S.I., and Rosenberg R.N. Vasoactive intestinal polypeptide: abundant immunoreactivity in neural cell lines and normal nervous tissue. Science 192 (1976) 907-908
6. Grisoni E., De Augustin J.C., and Kalhan S.C. Vasoactive intestinal polypeptide causes relaxation of the pyloric sphincter in the rabbit. J Pediatr Surg 28 (1993) 1117-1120
7. Greenberg B., Rhoden K., and Barnes P.J. Relaxant effects of vasoactive intestinal peptide and peptide histidine isoleucine in human and bovine pulmonary arteries. Blood Vessels 24 (1987) 45-50
8. Iwabuchi S., Ono S., Tanita T., et al. Vasoactive intestinal peptide causes nitric oxide-dependent pulmonary vasodilation in isolated rat lung. Respiration 64 (1997) 54-58
9. Gunaydin S., Imai Y., Takanashi Y., et al. The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproteronol and nitroglycerine. Cardiovasc Surg 10 (2002) 138-145
10. Eriksson L.S., Hagenfeldt L., Mutt V., et al. Influence of vasoactive intestinal polypeptide (VIP) on splanchnic and central hemodynamics in healthy subjects. Peptides 10 (1989) 481-484
11. Popma J.J., Smitherman T.C., Bedotto J.B., et al. Direct coronary vasodilation induced by intracoronary vasoactive intestinal peptide. J Cardiovasc Pharmacol 16 (1990) 1000-1006
12. Huang M., Shirahase H., and Rorstad O.P. Comparative study of vascular relaxation and receptor binding by PACAP and VIP. Peptides 14 (1993) 755-762
13. Institute of Laboratory Animal Resources (U.S.). Guide for the care and use of laboratory animals/Institute of Laboratory Animals Resources, Commission on Life Sciences, National Research Council (1996), National Academy Press, Washington (DC) 28-46
14. Davey A.M., Becker J.D., and Davis J.M. Meconium aspiration syndrome: physiological and inflammatory changes in a newborn piglet model. Pediatr Pulmonol 16 (1993) 101-108
15. Haydar A., Malhere T., Mauriat P., et al. Inhaled nitric oxide for postoperative pulmonary hypertension in patients with congenital heart disease. Lancet 340 (1992) 1545
16. Hill L.L., and Pearl R.G. Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension. J Appl Physiol 86 (1999) 1160-1164
17. Rimensberger P.C., Spahr-Schopfer I., Berner M., et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease. Circulation 103 (2001) 544-548
18. Zhao L., Mason N.A., Morrell N.W., et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104 (2001) 424-428
19. Ichinose F., Erana-Garcia J., Hromi J., et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 29 (2001) 1000-1005
20. Shekerdemian L.S., Ravn H.B., and Penny D.J. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 165 (2002) 1098-1102
21. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for PAH. N Engl J Med 346 (2002) 1896-1899
22. Rich S., and McLaughlin V.V. Endothelin receptor blockers in cardiovascular disease. Circulation 108 (2003) 2084-2086
23. McLaughlin V.V., Sitbon O., Badesch D.B., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 (2005) 244-249
24. Linder S., Barkhem T., Norberg A., et al. Structure and expression of the gene encoding the vasoactive intestinal peptide precursor. Proc Natl Acad Sci U S A 84 (1987) 605-609
25. Uddman T., and Sundler F. VIP nerves in human upper respiratory tract. Otorhinolaryngology 41 (1979) 221-226
26. Lundberg J.M., Hokfelt T., Kewenter J., et al. Substance P-, VIP- and enkephalin-like immunoreactivity in the human vagus nerve. Gastroenterology 77 (1979) 468-471
27. Martling C.R., Matran R., Alving K., et al. Innervation of lower airways and neuropeptide effects on bronchial and vascular tone in the pig. Cell Tissue Res 260 (1990) 223-233
28. Harmar A.J., Arimura A., Gozes I., et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50 (1998) 265-270
29. Schulz S., Rocken C., Mawrin C., et al. Clin Cancer Res 10 (2004) 8235-8242
30. Rawlings S.R., and Hëzareh M. Pituitary adenylate cyclase activating polypeptide and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Endocr Rev 17 (1996) 4-29
31. Petkov V., Mosgoeller W., Ziesche R., et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111 (2003) 1339-1346
32. Opgaard O.S., Knutsson M., De Vries R., et al. Vasoactive intestinal peptide has a direct positive inotropic effect on isolated human myocardial trabeculae. Clin Sci 101 (2001) 643-673
33. Pozo D., and Delgado M. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?. FASEB J 18 (2004) 1325-1334
34. Delgado M., Munoz-Elias E.J., Gomariz R.P., et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-κB and IFN regulatory factor 1 activation. J Immunol 162 (1999) 4685-4696
35. Schermuly R.T., Dony E., Ghofrani H.A., et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115 (2005) 2811-2821
36. Hirst S.J., Barnes P.J., and Twort C.H. PDGF isoform-induced proliferation and receptor expression in human cultured airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 270 (1996) L415-L428
37. Tomlinson P.R., Wilson J.W., and Stewart A.G. Salbutamol inhibits the proliferation of human airway smooth muscle cells grown in culture: relationship to elevated cAMP levels. Biochem Pharmacol 49 (1995) 1809-1819
38. Kristensen M., and Hansen T. Statistical analyses of repeated measures in physiological research: a tutorial. Adv Physiol Educ 28 (2004) 2-14